Aurobindo Receives FDA Approval for Tretinoin Gel USP, 0.01%
Published: January 13, 2025
East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Tretinoin Gel USP, 0.01%. Aurobindo Pharma’s Tretinoin Gel, are an AB-rated generic equivalent to the reference listed drug (RLD), Retin-A® Gel manufactured by Bausch Health US, LLC.
Tretinoin Gel are indicated for:
- Topical application in the treatment of acne vulgaris.